共 50 条
- [41] MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancerCANCER RESEARCH, 2020, 80 (04)Rastogi, PriyaToi, MasakazuMartin, MiguelO'Shaughnessy, JoyceHeadley, DesireeWei, JenniferCox, JoanneHarbeck, NadiaJohnston, Stephen
- [42] The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early + /HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trialsBREAST, 2024, 78Keskinkilic, MerveArayici, Mehmet EminBasbinar, YaseminEllidokuz, HulyaYavuzsen, TugbaOztop, Ilhan
- [43] Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Martin, MiguelHegg, RobertoKim, Sung-BaeSchenker, MichaelGrecea, DanielaGarcia-Saenz, Jose A.Papazisis, KonstantinosOuyang, QuchangLacko, AleksandraOksuzoglu, BernaReeves, James AndrewOkera, MeenaTesta, LauraShimizu, ChikakoWei, RanForrester, Tammy D.Munoz, MariaZimmermann, Annamaria H.Headley, DesireeJohnston, Stephen R. D.
- [44] Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast CancerCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 15 - 16O'Shaughnessy, Joyce A.Johnston, StephenHarbeck, NadiaToi, MasakazuIm, Young-HyuckReinisch, MatteaShao, ZhiminLehtinen, Pirkko Liisa KellokumpuHuang, Chiun-ShengTryakin, AlexeyGoetz, MatthewRugo, Hope S.Senkus, ElzbietaTesta, LauraAndersson, MichaelTamura, KenjiSteger, Guenther G.Del Mastro, LuciaCox, JoanneForrester, TammySherwood, SarahLi, XuelinWei, RanMartin, MiguelRastogi, Priya
- [45] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2023, 24 (01): : 77 - 90Johnston, Stephen R. D.Toi, MasakazuO'Shaughnessy, JoyceRastogi, PriyaCampone, MarioNeven, PatrickHuang, Chiun-ShengHuober, JensJaliffe, Georgina GarnicaCicin, IrfanTolaney, Sara M.Goetz, Matthew P.Rugo, Hope S.Senkus, ElzbietaTesta, LauraDel Mastro, LuciaShimizu, ChikakoWei, RanShahir, AshwinMunoz, MariaSan Antonio, BelenAndre, ValerieHarbeck, NadiaMartin, Miguel
- [46] Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive/HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR TrialCANCER RESEARCH, 2021, 81 (04)Munzone, ElisabettaAebi, StefanJanez, Noelia MartinezGuth, UweBellet, MeritxellPistilli, BarbaraBalic, MarijaRoschitzki-Voser, HeidiRegan, Meredith M.
- [47] Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2-high-risk breast cancerEXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 805 - 814Sammons, SarahMoore, HeatherCushman, JayceeHamilton, Erika
- [49] Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyLANCET ONCOLOGY, 2021, 22 (02): : 212 - 222Mayer, Erica L.Dueck, Amylou C.Martin, MiguelRubovszky, GaborBurstein, Harold J.Bellet-Ezquerra, MeritxellMiller, Kathy D.Zdenkowski, NicholasWiner, Eric P.Pfeiler, GeorgGoetz, MatthewRuiz-Borrego, ManuelAnderson, DanielNowecki, ZbigniewLoibl, SibylleMoulder, StacyRing, AlistairFitzal, FlorianTraina, TiffanyChan, ArleneRugo, Hope S.Lemieux, JulieHenao, FernandoLyss, AlanNovoa, Silvia AntolinWolff, Antonio C.Vetter, MarcusEgle, DanielMorris, Patrick G.Mamounas, Eleftherios P.Gil-Gil, Miguel J.Prat, AleixFohler, HannesMetzger Filho, OttoSchwarz, MagdalenaDuFrane, CarterFumagalli, DeboraTheall, Kathy PuyanaLu, Dongrui RayBartlett, Cynthia HuangKoehler, MariaFesl, ChristianDeMichele, AngelaGnant, Michael
- [50] A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)ANNALS OF ONCOLOGY, 2023, 34 : S323 - S324Hamilton, E.Loibl, S.Niikura, N.Rastogi, P.Saini, K. S.Gioni, I.Klinowska, T.Mayer, I.Stuart, M.Syta, E.Walding, A.Bachelot, T.